The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Synergy Satellite: Targeted drugs – scattered goals (sponsored by a grant from Novartis)
Affiliation
German Cancer Research Center & University Hospital Heidelberg
Country
Germany
1. Current Status, Position
- Head of Division, CCU Pediatric Oncology, DKFZ Heidelberg;
- Head of Division, Pediatric Brain Tumors, University Hospital Heidelberg.
2. Education
- Training in Pediatrics, Pediatric Oncology and Neonatal Medicine at University of Göttingen Medical School;
- Postdoctoral Fellow in Molecular Biology of Histone Family Variants in Cancer at University of Göttingen;
- W3 joined professorship at DKFZ/University Hospital Heidelberg and Head of Division CCU Pediatric Oncology since 2005.
3. Research Area
- Clinical Specialization in Pediatric Neurooncology;
- Interest in Personalized Pediatric Oncology, novel targeted treatment approaches, clinical translation of novel targets based on mechanism of action;
- Evaluation of individual members of histone deacetylase family as selective drug targets and their mechanism of action.
Conflict of interest: Consultant for Astra Zeneca and Novartis and Research Grant Recipient from Bayer Healthcare.